ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/26mar1477

Pharmacological Contrasts Between Caffeine and Shilajit: Implications for Performance and Health

Sanskar Singh[1*]; Vineet Kumar Singh[2]; Sanjeev Kumar[3]; Prashant Kumar Sharma[4]; Pushpendra Kannojia[3]; Deeksha Sharma[4]

[1]Research Scholar, BIU College of pharmacy, Bareilly International University, Bareilly, Uttar Pradesh, India.
[2] Associate Professor, BIU College of pharmacy, Bareilly International University, Bareilly, Uttar Pradesh, India.
[3]Professor, BIU College of pharmacy, Bareilly International University, Bareilly, Uttar Pradesh, India.
[4] Assistant Professor, BIU College of pharmacy, Bareilly International University, Bareilly, Uttar Pradesh, India

Corresponding Author: Sanskar Singh[*]

Publication Date: 2026/03/28

Abstract:

- ***Background:***
Caffeine and Asphaltum punjabianum (Shilajit) are widely consumed bioactive substances that represent fundamentally different pharmacological paradigms. Caffeine is a well characterized methylxanthine with rapid central nervous system stimulant effects, whereas Shilajit is a complex herbomineral phytocomplex traditionally used in Ayurvedic medicine as a rasayana and adaptogen, with emerging evidence of systemic regulatory effects.

- ***Objectives:***
To critically synthesize contemporary preclinical and clinical literature on the pharmacokinetics, molecular mechanisms, therapeutic applications, and safety profiles of caffeine and Shilajit, and to contrast their modes of action while cautiously exploring potential interactions.

- ***Materials and Methods:***
A narrative review of relevant preclinical and clinical studies was conducted, focusing on the pharmacological mechanisms, biological effects, and safety considerations of caffeine and Shilajit. Literature addressing theoretical interactions and regulatory challenges was also examined.

- ***Results:***
Caffeine exerts acute neuromodulatory effects primarily through antagonism of adenosine A_1 and A_2A receptors, leading to transient improvements in alertness, cognition, and physical performance. In contrast, Shilajit demonstrates antioxidant, anti-inflammatory, mitochondrial, and metabolic regulatory properties, suggesting a systems-level influence on cellular resilience and bioenergetics. No experimental studies directly evaluating combined use were identified, though theoretical complementarity and potential antagonism were discussed. Key challenges include Shilajit standardization, contamination risks, and regulatory limitations.

- ***Conclusion:***
Caffeine and Shilajit possess distinct and well-defined pharmacological roles, with caffeine acting as an acute stimulant and Shilajit functioning as a long-term adaptogenic modulator. However, rigorous mechanistic and clinical investigations are required before any claims regarding combined or synergistic benefits can be substantiated.

Keywords: *Caffeine; Asphaltum Punjabianum; Shilajit; Adenosine Antagonism; Fulvic Acid; Ergogenic Aid.*

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/26mar1477

How to Cite: Sanskar Singh; Vineet Kumar Singh; Sanjeev Kumar; Prashant Kumar Sharma; Pushpendra Kannojia; Deeksha Sharma (2026) Pharmacological Contrasts Between Caffeine and Shilajit: Implications for Performance and Health. *International Journal of Innovative Science and Research Technology*, 11(3), 2446-2453. https://doi.org/10.38124/ijisrt/26mar1477

I. INTRODUCTION

The global use of bioactive substances to enhance alertness, physical performance, and overall resilience continues to increase, driven by modern lifestyle demands and the expanding nutraceutical market[1]. Among these substances, caffeine and *Asphaltum punjabianum* (Shilajit) occupy distinct yet increasingly overlapping domains of consumption. Caffeine is one of the most widely consumed psychoactive compounds worldwide and is extensively studied for its acute stimulatory effects on the central nervous system[2]. In contrast, Shilajit is a traditional herbomineral preparation used for centuries in Ayurvedic medicine, primarily valued for its adaptogenic and rejuvenative properties rather than immediate stimulation[3]. This distinction underscores a fundamental pharmacological difference between classic stimulants and adaptogenic substances, which modulate stress responses and promote homeostasis without provoking acute excitation[4].

Caffeine (1,3,7-trimethylxanthine) exerts its primary pharmacological effects through antagonism of adenosine A_1 and A_{2A} receptors, leading to increased neuronal excitability and enhanced dopaminergic signalling. These mechanisms underpin its well-documented effects on vigilance, cognitive performance, and exercise capacity, as well as its recognized limitations related to tolerance, sleep disruption, and anxiety. Consequently, caffeine represents a paradigmatic example of an acute, receptor-specific stimulant with rapid onset and transient effects[5].

By contrast, Shilajit is not a single chemical entity but a complex phytocomplex formed through the prolonged humification of plant and microbial matter under geological conditions[6]. Its bioactivity is attributed primarily to humic substances, including fulvic acid, dibenzo-α-pyrones, and associated trace minerals[7]. Contemporary research suggests that these components exert pleiotropic effects, including antioxidant and anti-inflammatory actions, modulation of mitochondrial bioenergetics, and support of cellular homeostasis[8]. These properties align with its traditional classification as a rasayana, a category of agents believed to enhance systemic resilience and longevity[9].

Despite their fundamentally different pharmacological profiles, caffeine and Shilajit are increasingly co-marketed and co-consumed in dietary supplements aimed at improving energy, performance, and stress tolerance. However, the scientific literature has largely examined these agents in isolation, with minimal effort to contextualize their contrasting mechanisms or to evaluate potential interactions. This disconnect is particularly relevant given the mechanistic divergence between caffeine's acute neuromodulatory action and Shilajit's proposed systems-level, adaptogenic effects.

The present narrative review critically examines the pharmacology, therapeutic evidence, and safety considerations of caffeine and *Asphaltum punjabianum* (Shilajit) in parallel. Rather than asserting unverified synergistic effects, the review emphasizes a cautious comparative framework, identifying mechanistic contrasts, theoretical interactions, and key gaps in current knowledge. By doing so, it aims to provide a balanced scientific basis for future experimental and clinical investigations into the rational use of these widely consumed bioactive substances.

II. CAFFEINE: PHARMACOLOGICAL PROFILE AND THERAPEUTIC EVIDENCE

A. Chemical Identity and Exposure Sources

Caffeine (1,3,7-trimethylxanthine) is a naturally occurring methylxanthane alkaloid widely distributed in plant species such as *Coffea arabica*, *Camellia sinensis*, *Paullinia cupana*, and *Theobroma cacao*[10]. In addition to dietary exposure through coffee, tea, and chocolate, caffeine is extensively incorporated into pharmaceuticals, sports supplements, and energy products, resulting in highly variable patterns of intake across populations[11]. While moderate consumption is generally considered safe, the widespread availability of concentrated formulations has increased the risk of excessive and unintentional dosing[12].

B. Pharmacokinetics and Interindividual Variability

Following oral ingestion, caffeine is rapidly and almost completely absorbed, with peak plasma concentrations typically achieved within 30-60 minutes. Its high lipophilicity allows efficient distribution across biological membranes, including the blood brain barrier and placenta[13]. Hepatic metabolism is mediated predominantly by cytochrome P450 1A2 (CYP1A2), producing paraxanthine as the principal active metabolite[14]. A critical feature of caffeine pharmacokinetics is marked interindividual variability. Genetic polymorphisms in CYP1A2, hormonal status, smoking behaviour, pregnancy, and concomitant medications substantially influence caffeine clearance and elimination half-life[15]. This variability contributes to heterogeneous physiological responses and complicates universal dosing recommendations, particularly in performance and clinical contexts[16].

C. Mechanisms of Action

At physiologically relevant concentrations, caffeine's primary mechanism of action is competitive antagonism of adenosine A_1 and A_{2A} receptors. By inhibiting adenosine-mediated neuromodulation, caffeine increases neuronal firing rates and enhances neurotransmitter release, particularly within dopaminergic and noradrenergic pathways[17]. Antagonism of A_{2A} receptors in the striatum is especially relevant for psychomotor activation and perceived alertness[18].

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/26mar1477



Fig 1: Mechanism of Action of Caffeine as a Competitive Antagonist of Adenosine A_1 and A_{2A} Receptors, Leading to Increased Neurotransmission and Dopaminergic Activity.

Additional mechanisms, including phosphodiesterase inhibition and intracellular calcium mobilization, occur only at supraphysiological concentrations and are unlikely to contribute meaningfully to effects observed with typical dietary or ergogenic doses. This distinction is important to avoid overinterpretation of mechanistic findings derived from high dose in vitro models.

D. Evidence-Based Physiological Effects



Fig 2: Key Evidence-Based Physiological Effects of Caffeine.

➢ *Central Nervous System and Cognition*

Caffeine reliably reduces subjective fatigue and improves vigilance, reaction time, and sustained attention, particularly under conditions of sleep deprivation or cognitive fatigue. Effects on higher-order executive function are inconsistent and appear dose-dependent, with excessive

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/26mar1477

intake increasing anxiety and impairing task performance in susceptible individuals[19,20].

➢ *Exercise Performance*

Caffeine is among the most consistently supported ergogenic aids, with moderate improvements observed in endurance capacity, strength, and power output[21]. Proposed mechanisms include reduced perceived exertion, enhanced motor unit recruitment, and altered substrate utilization[22]. However, habitual intake, genetic variability, and tolerance substantially modulate responsiveness, limiting uniform effectiveness[23,24].

➢ *Cardiovascular and Metabolic Effects*

A cute caffeine ingestion produces transient increases in blood pressure and sympathetic activity, though tolerance develops rapidly in habitual consumers[25]. Large observational studies generally do not associate moderate intake with increased cardiovascular risk; however, individuals with hypertension, arrhythmias, or anxiety disorders may exhibit heightened sensitivity[26].

➢ *Analgesic Adjuvant Use*

Caffeine is frequently included in combination analgesic formulations, where it provides modest but reproducible enhancement of pain relief[27]. Its clinical utility in this context is supported by meta-analyses, although the magnitude of benefit remains limited[28].

E. Safety, Tolerance, and Clinical Boundaries

Caffeine exhibits a favorable safety profile when consumed within commonly recommended limits (≤400 mg/day in healthy adults). Nevertheless, repeated exposure leads to tolerance through adaptive upregulation of adenosine receptors, attenuating stimulant and cardiovascular effects. Abrupt cessation following chronic use can produce a well-characterized withdrawal syndrome, underscoring its capacity to induce mild physical dependence[29].

Vulnerable populations including pregnant individuals, patients with cardiovascular disease, sleep disorders, or anxiety require cautious intake. Importantly, the growing availability of high dose caffeine products necessitates clearer consumer education and regulatory oversight to mitigate misuse[30].

III. *ASPHALTUM PUNJABIANUM* (SHILAJIT): COMPOSITION, EVIDENCE, AND LIMITATIONS

A. Origin and Traditional Context

Asphaltum punjabianum, commonly known as Shilajit, is a naturally occurring resinous material exuded from mountainous rock formations, particularly in the Himalayan and adjacent regions. It is formed through the prolonged humification of plant and microbial matter under geological pressure and temperature. In Ayurvedic medicine, Shilajit is classified as a rasayana, a category of agents traditionally associated with rejuvenation and systemic support. While such traditional classifications provide historical context, modern scientific evaluation requires independent validation through chemical characterization and controlled experimental studies.

B. Chemical Composition and Standardization Challenges

Shilajit is a heterogeneous phytocomplex rather than a single chemical entity. Its composition varies substantially depending on geographic origin, botanical precursors, seasonal factors, and processing methods. The major bioactive fractions include humic substances, particularly fulvic acid, along with dibenzo-α-pyrones and associated trace minerals.

A central challenge in Shilajit research is the lack of standardized preparations. Many studies utilize extracts with poorly defined composition, limiting reproducibility and cross-study comparison. Current commercial products are often standardized to fulvic acid content; however, fulvic acid alone is unlikely to fully account for Shilajit's reported bioactivity. Comprehensive chemical fingerprinting and validated quality control markers are therefore essential for advancing both research and clinical translation[31].

C. Mechanistic Evidence and Biological Plausibility

Proposed mechanisms of Shilajit action are derived primarily from *in vitro* and animal studies. These include antioxidant and anti-inflammatory effects, modulation of mitochondrial function, and facilitation of mineral and nutrient transport across cell membranes. Fulvic acid and dibenzo-α-pyrones have been implicated in protecting mitochondrial membranes from oxidative damage and supporting electron transport processes, thereby enhancing cellular energy efficiency[32,33].

While these mechanisms are biologically plausible, it is important to note that direct evidence linking Shilajit supplementation to sustained improvements in mitochondrial bioenergetics in humans remains limited. Consequently, mechanistic claims should be interpreted cautiously and contextualized within the predominantly preclinical nature of the data.

D. Therapeutic Evidence: Human and Preclinical Data

➢ *Human Evidence*

Clinical data on Shilajit are limited but emerging. Small randomized and observational studies have reported improvements in oxidative stress markers, endothelial function, and select reproductive parameters following supplementation with purified Shilajit preparations. However, these studies are typically characterized by modest sample sizes, short intervention durations, and variability in extract standardization, which constrain the strength of clinical inference[34,35].

➢ *Preclinical Evidence*

Animal and in vitro studies suggest potential benefits in metabolic regulation, bone health, spermatogenesis, immune modulation, and tissue regeneration[36,37]. Notably, recent biomaterials research has explored Shilajit incorporation into scaffolds for cartilage and bone regeneration, highlighting its possible utility beyond oral

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/26mar1477

supplementation[38]. While these findings are innovative, they remain preliminary and cannot be directly extrapolated to human therapeutic use.

E. Safety, Contamination Risk, and Regulatory Status

Safety considerations represent a major limiting factor in Shilajit use. Raw or inadequately processed Shilajit may contain heavy metals, mycotoxins, and microbial contaminants[39]. Purification and rigorous quality control are therefore essential prerequisites for human consumption[7].

From a regulatory perspective, Shilajit is classified as a dietary supplement or traditional medicine in many jurisdictions and lacks approval as a pharmaceutical agent by major regulatory authorities such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA)[40,41]. Consequently, its clinical use should be approached with caution, emphasizing purified preparations, transparent labeling, and adherence to established safety guidelines.

IV. COMPARATIVE PHARMACOLOGY AND HYPOTHESIZED INTERACTIONS

➢ *Distinct Pharmacological Paradigms*

Caffeine and *Asphaltum punjabianum* (Shilajit) exemplify fundamentally different approaches to modulating human physiology. Caffeine acts as a direct neuromodulator, acutely altering neurotransmission through adenosine receptor antagonism and producing rapid but transient increases in alertness and performance. In contrast, Shilajit is proposed to function as a systems-level modulator, influencing cellular homeostasis, oxidative balance, and metabolic resilience over longer time scales[42].

This distinction has important implications for both efficacy and risk. Caffeine's acute effects are predictable and dose dependent but are accompanied by tolerance, withdrawal, and sleep disruption with repeated use. Shilajit, while lacking acute stimulant properties, may influence baseline physiological capacity, although such effects are less precisely defined and supported primarily by preclinical evidence.

➢ *Comparative Pharmacological Profiles*

Table 1 : Comparative Pharmacological Profiles Caffeine & Asphaltum punjabianum (Shilajit)

Feature	Caffeine	*Asphaltum punjabianum* (Shilajit)
Chemical nature	Single, well-defined alkaloid	Complex, heterogeneous phytocomplex
Primary mechanism	Adenosine A_1/A_{2A} antagonism	Antioxidant, anti-inflammatory, mitochondrial support
Onset of action	Minutes	Days to weeks
Duration of effect	Short	Prolonged with repeated use
Evidence base	Extensive human data	Limited human, extensive preclinical
Tolerance potential	High	No clear evidence
Key risks	Anxiety, insomnia, cardiovascular effects	Contamination, lack of standardization

➢ *Hypothesized Interaction Pathways*

To date, no pharmacokinetic or pharmacodynamic studies have directly examined the combined administration of caffeine and Shilajit. Any discussion of interaction must therefore remain theoretical and hypothesis driven.

Several mechanistic pathways warrant cautious consideration. Shilajit's antioxidant and anti-inflammatory properties may theoretically counterbalance oxidative stress associated with sustained caffeine consumption[43]. Additionally, proposed effects of Shilajit on mitochondrial efficiency could support increased metabolic demand during periods of caffeine-induced neural or physical activation. Conversely, Shilajit's adaptogenic or homeostatic influences could attenuate caffeine's stimulant effects, resulting in neutral or even antagonistic interactions.

Importantly, the possibility of no meaningful interaction cannot be excluded. Given the absence of direct evidence, claims of synergy are premature and unsupported. Controlled experimental studies are required to determine whether combined use confers additive, neutral, or antagonistic effects.

➢ *Framework for Future Investigation*

Future research should prioritize mechanistic and clinical clarity over assumed benefit. Key study designs include:

- Pharmacokinetic studies evaluating whether Shilajit alters caffeine absorption, metabolism, or clearance.
- Randomized controlled trials comparing caffeine alone, Shilajit alone, combined administration, and placebo.
- Biomarker-driven assessments focusing on oxidative stress, mitochondrial function, sleep quality, and cognitive or physical performance outcomes[44].
- Such approaches would allow evidence-based determination of interaction profiles and inform rational supplement formulation.

V. RESEARCH GAPS AND FUTURE DIRECTIONS

Despite extensive investigation of caffeine and growing interest in *Asphaltum punjabianum* (Shilajit), several critical gaps remain in the current literature. Addressing these limitations is essential for advancing both mechanistic understanding and evidence-based application.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/26mar1477

First, interaction studies are entirely absent. No pharmacokinetic or pharmacodynamic investigations have evaluated the combined administration of caffeine and Shilajit. Such studies are necessary to determine whether Shilajit influences caffeine absorption, metabolism (particularly CYP1A2 activity), or central nervous system effects.

Second, human clinical evidence for Shilajit remains limited in scope and rigor. Existing studies are often constrained by small sample sizes, short intervention periods, and heterogeneity in extract standardization. Larger, well-controlled randomized trials using chemically characterized preparations are required to establish efficacy, dose–response relationships, and long-term safety.

Third, mechanistic claims for Shilajit require stronger translational validation. While antioxidant and mitochondrial effects are supported by preclinical data, direct confirmation in humans using validated biomarkers of mitochondrial function, oxidative stress, and metabolic efficiency is largely lacking.

Fourth, standardization and regulatory challenges represent a major barrier to reproducible research. Development of validated chemical fingerprints, reference standards, and quality-control benchmarks is essential for cross-study comparison and regulatory acceptance.

Finally, future research should adopt comparative and factorial study designs, directly contrasting acute stimulatory strategies (e.g., caffeine) with adaptogenic or foundational approaches (e.g., Shilajit). Such studies would clarify whether these agents exert additive, neutral, or antagonistic effects when used concurrently, thereby informing rational nutraceutical formulation and evidence-based consumer guidance.

VI. CONCLUSION

Caffeine and *Asphaltum punjabianum* (Shilajit) represent two fundamentally distinct approaches to modulating human physiology. Caffeine is a well-characterized central nervous system stimulant with predictable, acute effects mediated primarily through adenosine receptor antagonism. Its benefits for alertness, cognitive performance, and physical endurance are supported by extensive human evidence, albeit tempered by tolerance, sleep disruption, and individual variability.

In contrast, Shilajit is a complex herbomineral phytocomplex traditionally employed as an adaptogenic and rejuvenative agent. Emerging scientific evidence suggests potential roles in antioxidant defense, mitochondrial support, and systemic homeostasis; however, these effects are supported predominantly by preclinical data and limited clinical trials. Issues related to standardization, contamination risk, and regulatory oversight remain significant constraints on its broader clinical translation.

While the concurrent use of caffeine and Shilajit is increasingly observed in nutraceutical contexts, claims of synergistic benefit remain unsubstantiated. Current evidence supports neither synergy nor antagonism, underscoring the need for controlled mechanistic and clinical investigations. Until such data are available, these substances should be understood and applied according to their distinct pharmacological profiles rather than presumed complementary effects.

Overall, this review highlights the importance of scientific restraint when integrating traditional and modern bioactive agents. A rigorous, hypothesis-driven research agenda grounded in chemical standardization, translational biomarkers, and well-designed clinical trials is essential to determine the rational role of these widely consumed compounds in human health and performance.

- *Ethical Approval – N/A*
- *Funding- This Research Received no External Funding*
- *Conflict of Interest- The Authors Declare no Conflict of Interest.*
- *CRediT Authorship Contribution Statement-*

- Sanskar Singh: Conceptualization, Writing – original draft.
- Vineet Kumar Singh: Methodology.
- Sanjeev Kumar: Methodology.
- Pushpendra Kannojia: Data curation.
- Deeksha Sharma: Data curation.

ACKNOWLEDGEMENTS

The authors would like to express their sincere gratitude to their institution for providing the necessary facilities and support to carry out this research. The authors also thank colleagues and reviewers for their valuable comments and suggestions, which helped improve the quality of this manuscript.

REFERENCES

[1]. Grand View Research. (2023). *Nutraceuticals market size, share & trends analysis report* [Market analysis report]. https://www.grandviewresearch.com/industry-analysis/nutraceuticals-market
[2]. Nehlig, A. (2018). Interindividual differences in caffeine metabolism and factors driving caffeine consumption. *Pharmacological Reviews, 70*(2), 384–411. https://doi.org/10.1124/pr.117.014407
[3]. Wilson, E., Rajamanickam, G. V., Dubey, G. P., Klose, P., Musial, F., Saha, F. J., Rampp, T., Michalsen, A., & Dobos, G. J. (2021). Review on shilajit used in traditional Indian medicine. *Journal of Ethnopharmacology, 265*, Article 113157. https://doi.org/10.1016/j.jep.2020.113157

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/26mar1477

[4]. Panossian, A., & Wikman, G. (2010). Effects of adaptogens on the central nervous system and the molecular mechanisms associated with their stress-protective activity. *Pharmaceuticals, 3*(1), 188–224. https://doi.org/10.3390/ph3010188

[5]. Fredholm, B. B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E. E. (1999). Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. *Pharmacological Reviews, 51*(1), 83–133. https://doi.org/10.1016/S0031-6997(24)01396-6

[6]. Ghosal, S. (2000). Chemical constituents of Shilajit, the ancient herbo-mineral panacea. *Oriental Pharmacy and Experimental Medicine, 1*(1), 19–30

[7]. Schepetkin, I. A., Khlebnikov, A. I., Ahmetzhanov, D. R., & Ozek, G. (2022). Chemical composition and therapeutic potential of humic substances from mumie (Shilajit): A comprehensive review. *Molecules, 27*(18), 6072. https://doi.org/10.3390/molecules27186072

[8]. Carrasco-Gallardo, C., Guzmán, L., & Maccioni, R. B. (2012). Shilajit: A natural phytocomplex with potential procognitive activity. *International Journal of Alzheimer's Disease*, 2012, 674142. https://doi.org/10.1155/2012/674142

[9]. Sharma, P., Jha, J., & Pathak, S. (2022). Ayurvedic concept of Rasayana therapy and its role in promoting longevity and resilience. *Journal of Ethnopharmacology*, 296, 115416. https://doi.org/10.1016/j.jep.2022.115416

[10]. Heckman, M. A., Weil, J., & Gonzalez de Mejia, E. (2010). Caffeine (1,3,7-trimethylxanthine) in foods: A comprehensive review on consumption, functionality, safety, and regulatory matters. *Journal of Food Science,* 75(3), R77–R87. https://doi.org/10.1111/j.1750-3841.2010.01561.x

[11]. Temple, J. L., Bernard, C., Lipshultz, S. E., Czachor, J. D., Westphal, J. A., & Mestre, M. A. (2017). The safety of ingested caffeine: A comprehensive review. *Frontiers in Psychiatry*, 8, 80. https://doi.org/10.3389/fpsyt.2017.00080

[12]. Wikoff, D., Welsh, B. T., Henderson, R., Brorby, G. P., Britt, J., Myers, E., Goldberger, J., Lieberman, H. R., O'Brien, C., Peck, J., Tenenbein, M., Weaver, C., Harvey, S., Urban, J., & Doepker, C. (2017). Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. *Food and Chemical Toxicology*, 109(Pt 1), 585–648. https://doi.org/10.1016/j.fct.2017.04.002

[13]. Chen, J. F., Eltzschig, H. K., & Fredholm, B. B. (2010). Adenosine receptors as drug targets-What are the challenges? *Nature Reviews Drug Discovery*, *12*(4), 265–286. https://doi.org/10.1038/nrd3955

[14]. Arnaud, M. J. (2011). Pharmacokinetics and metabolism of natural methylxanthines in animal and man. In *Methylxanthines* (pp. 33–91). Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-13443-2_3

[15]. Yang, A., Palmer, A. A., & de Wit, H. (2010). Genetics of caffeine consumption and responses to caffeine. *Psychopharmacology*, *211*(3), 245–257. https://doi.org/10.1007/s00213-010-1900-1

[16]. Reyes, C. M., & Cornelis, M. C. (2018). Caffeine in the diet: Country-level consumption and guidelines. *Nutrients*, *10*(11), 1772. https://doi.org/10.3390/nu10111772

[17]. Ferré, S. (2010). Role of the central ascending neurotransmitter systems in the psychostimulant effects of caffeine. *Journal of Alzheimer's Disease*, *20*(Suppl 1), S35–S49. https://doi.org/10.3233/JAD-2010-1400

[18]. Huang, Z. L., Qu, W. M., Eguchi, N., Chen, J. F., Schwarzschild, M. A., Fredholm, B. B., Urade, Y., & Hayaishi, O. (2005). Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. *Nature Neuroscience*, *8*(7), 858–859. https://doi.org/10.1038/nn1491

[19]. McLellan, T. M., Caldwell, J. A., & Lieberman, H. R. (2016). A review of caffeine's effects on cognitive, physical and occupational performance. *Neuroscience & Biobehavioral Reviews, 71*, 294–312. https://doi.org/10.1016/j.neubiorev.2016.09.001

[20]. Smith, A. P. (2020). Caffeine, mental health, and psychiatric disorders. *Journal of Alzheimer's Disease, 74*(1), 17–28. https://doi.org/10.3233/JAD-191190

[21]. Guest, N. S., VanDusseldorp, T. A., Nelson, M. T., Grgic, J., Schoenfeld, B. J., Jenkins, N. D. M., Arent, S. M., Antonio, J., Stout, J. R., Trexler, E. T., Smith-Ryan, A. E., Goldstein, E. R., Kalman, D. S., & Campbell, B. I. (2021). International society of sports nutrition position stand: Caffeine and exercise performance. *Journal of the International Society of Sports Nutrition, 18*(1), 1. https://doi.org/10.1186/s12970-020-00383-4

[22]. Glaister, M., & Gissane, C. (2018). Caffeine and physiological responses to submaximal exercise: A meta-analysis. *International Journal of Sports Physiology and Performance, 13*(4), 402–411. https://doi.org/10.1123/ijspp.2017-0312

[23]. Pickering, C., & Kiely, J. (2019). Are the current guidelines on caffeine use in sport optimal for everyone? Inter-individual variation in caffeine ergogenicity, and a move towards personalised sports nutrition. *Sports Medicine, 49*(1), 7–16. https://doi.org/10.1007/s40279-018-0997-9

[24]. Southward, K., Rutherfurd-Markwick, K. J., & Ali, A. (2018). The effect of acute caffeine ingestion on endurance performance: A systematic review and meta-analysis. *Sports Medicine, 48*(8), 1913–1928. https://doi.org/10.1007/s40279-018-0939-8

[25]. Mesas, A. E., Leon-Muñoz, L. M., Rodriguez-Artalejo, F., & Lopez-Garcia, E. (2011). The effect of coffee on blood pressure and cardiovascular disease in hypertensive individuals: A systematic review and meta-analysis. *The American Journal of Clinical Nutrition*, *94*(4), 1113–1126. https://doi.org/10.3945/ajcn.111.016667

[26]. Ding, M., Bhupathiraju, S. N., Satija, A., van Dam, R. M., & Hu, F. B. (2014). Long-term coffee consumption and risk of cardiovascular disease: A systematic review and a dose-response meta-analysis of prospective

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/26mar1477

cohort studies. *Circulation*, *129*(6), 643–659. https://doi.org/10.1161/CIRCULATIONAHA.113.005925

[27]. Derry, C. J., Derry, S., & Moore, R. A. (2014). Caffeine as an analgesic adjuvant for acute pain in adults. *Cochrane Database of Systematic Reviews*, *2014*(12), CD009281. https://doi.org/10.1002/14651858.CD009281.pub3

[28]. Fioravanti, M., Buckley, J., & Lisi, C. (2011). Caffeine as an analgesic adjuvant for acute pain in adults. *Pain Medicine*, *12*(7), 1072–1079. https://doi.org/10.1111/j.1526-4637.2011.01146.x

[29]. Juliano, L. M., & Griffiths, R. R. (2004). A critical review of caffeine withdrawal: Empirical validation of symptoms and signs, incidence, severity, and associated features. *Psychopharmacology*, *176*(1), 1–29. https://doi.org/10.1007/s00213-004-2000-x

[30]. Pomeranz, J. L., Munsell, C. R., & Harris, J. L. (2018). Energy drinks: An emerging public health hazard for youth. *Journal of Public Health Policy*, *39*(3), 320–333. https://doi.org/10.1057/s41271-018-0137-9

[31]. Khattar, V., & Wal, P. (2019). Shilajit: A review of its chemical composition, pharmacological properties, and clinical applications. *International Journal of Research in Pharmaceutical Sciences*, *10*(2), 1040–1049. https://doi.org/10.26452/ijrps.v10i2.384

[32]. Bhattacharyya, S., Pal, D., & Gupta, A. K. (2009). Shilajit dibenzo-α-pyrones: Mitochondria targeted antioxidants. *Pharmacologyonline*, *2*, 690–698.

[33]. Jha, N. K., Sharma, A., Jha, S. K., Ojha, S., Chellappan, D. K., Gupta, G., Singh, S. K., & Dua, K. (2021). Shilajit: A natural phytocomplex with potential procognitive and neuroprotective activity. *International Journal of Molecular Sciences*, *22*(1), 463. https://doi.org/10.3390/ijms22010463

[34]. Biswas, T. K., Pandit, S., Mondal, S., Biswas, S. K., Jana, U., Ghosh, T., Tripathi, P. C., & Debnath, P. K. (2010). Clinical evaluation of spermatogenic activity of processed Shilajit in oligospermia. *Andrologia*, *42*(1), 48–56. https://doi.org/10.1111/j.1439-0272.2009.00956.x

[35]. Pandit, S., Biswas, S., Jana, U., De, R. K., Mukhopadhyay, S. C., & Biswas, T. K. (2016). Clinical evaluation of purified Shilajit on testosterone levels in healthy volunteers. *Andrologia*, *48*(5), 570–575. https://doi.org/10.1111/and.12482

[36]. Cornejo, A., Jiménez, J. M., Caballero, L., Melo, F., & Maccioni, R. B. (2011). Fulvic acid inhibits aggregation and promotes disassembly of tau fibrils associated with Alzheimer's disease. *Journal of Alzheimer's Disease*, *27*(1), 143–153. https://doi.org/10.3233/JAD-2011-110623

[37]. Stohs, S. J. (2014). Safety and efficacy of shilajit (mumie, moomiyo). *Phytotherapy Research*, *28*(4), 475–479. https://doi.org/10.1002/ptr.5018

[38]. Gupta, A., Kumar, S., & Srivastava, A. (2021). Shilajit: A novel biomaterial for bone tissue engineering. *International Journal of Biological Macromolecules*, *183*, 1875–1885. https://doi.org/10.1016/j.ijbiomac.2021.05.188

[39]. Garcia, L. L., Rode, D., & Schulze, H. (2018). Contaminants in botanical dietary supplements: A review of current analytical challenges and regulatory perspectives. *Journal of Agricultural and Food Chemistry*, *66*(5), 1063–1072. https://doi.org/10.1021/acs.jafc.7b05902

[40]. Smith, A., & Atkin, A. (2020). Challenges in researching combination dietary supplements. *Journal of Dietary Supplements*, *17*(3), 261–263. https://doi.org/10.1080/19390211.2020.1740164

[41]. U.S. Food and Drug Administration. (2024, January 10). *FDA 101: Dietary supplements*. https://www.fda.gov/consumers/consumer-updates/fda-101-dietary-supplements

[42]. Jha, N. K., Sharma, A., Jha, S. K., Ojha, S., Chellappan, D. K., Gupta, G., Singh, S. K., & Dua, K. (2021). Shilajit: A natural phytocomplex with potential procognitive and neuroprotective activity. *International Journal of Molecular Sciences, 22*(1), 463. https://doi.org/10.3390/ijms22010463

[43]. Wang, Y., Wang, S., & Cui, W. (2014). Caffeine-induced oxidative stress and antioxidant defense. *Oxidative Medicine and Cellular Longevity, 2014*, Article 536690. https://doi.org/10.1155/2014/536690

[44]. Ioannidis, J. P. A. (2018). The challenge of reforming nutritional epidemiologic research. *JAMA, 320*(10), 969–970. https://doi.org/10.1001/jama.2018.11025